Research ExplorerPublicationsPopulation-based Study of Perioperative Mortality After Retr...

Population-based Study of Perioperative Mortality After Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Germ Cell Tumors.

Standard

Population-based Study of Perioperative Mortality After Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Germ Cell Tumors. / Capitanio, Umberto; Jeldres, Claudio; Perrotte, Paul; Isbarn, Hendrik; Crépel, Maxime; Cloutier, Vincent; Baillargeon-Gagne, Sara; Shariat, Shahrokh F; Duclos, Alain; Arjane, Philippe; Widmer, Hugues; Saad, Fred; Montorsi, Francesco; Karakiewicz, Pierre I.

In: UROLOGY, Vol. 74, No. 2, 2, 2009, p. 373-377.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Capitanio, U, Jeldres, C, Perrotte, P, Isbarn, H, Crépel, M, Cloutier, V, Baillargeon-Gagne, S, Shariat, SF, Duclos, A, Arjane, P, Widmer, H, Saad, F, Montorsi, F & Karakiewicz, PI 2009, 'Population-based Study of Perioperative Mortality After Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Germ Cell Tumors.', UROLOGY, vol. 74, no. 2, 2, pp. 373-377. <http://www.ncbi.nlm.nih.gov/pubmed/19501893?dopt=Citation>

APA

Capitanio, U., Jeldres, C., Perrotte, P., Isbarn, H., Crépel, M., Cloutier, V., Baillargeon-Gagne, S., Shariat, S. F., Duclos, A., Arjane, P., Widmer, H., Saad, F., Montorsi, F., & Karakiewicz, P. I. (2009). Population-based Study of Perioperative Mortality After Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Germ Cell Tumors. UROLOGY, 74(2), 373-377. [2]. http://www.ncbi.nlm.nih.gov/pubmed/19501893?dopt=Citation

Vancouver

Capitanio U, Jeldres C, Perrotte P, Isbarn H, Crépel M, Cloutier V et al. Population-based Study of Perioperative Mortality After Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Germ Cell Tumors. UROLOGY. 2009;74(2):373-377. 2.

Bibtex

@article{2475695500a4494788fd15291054a7c6,
title = "Population-based Study of Perioperative Mortality After Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Germ Cell Tumors.",
abstract = "OBJECTIVES: To determine whether retroperitoneal lymphadenectomy (RPLND) perioperative mortality (PM) rates reported from a center of excellence (Indiana University: 0% for primary and 0.8% for postchemotherapy RPLND) are applicable to institutions at large. METHODS: We used the data from 882 assessable patients with nonseminomatous testicular germ cell tumor treated with RPLND from 1988 to 1997 accessed from the Surveillance, Epidemiology, and End Results (SEER) database. These data did not include data from Indiana University. The observed PM rates were stratified according to age and SEER stage. RESULTS: The median age at RPLND was 29 years. Of the 882 cases, 435 (49.3%) were performed for localized (Stage I), 380 (43.1%) for regional (Stage II), and 67 (7.6%) for metastatic (Stage III) SEER stage. Of the 882 patients, 7 patients died during the initial 90 days after RPLND, for a 0.8% PM rate. PM increased with increasing age: /=40 years, 2.7% (chi(2) trend test, P = .002). PM also increased with increasing stage: 0.0% for localized, 0.8% for regional, and 6.0% for metastatic disease (chi(2) trend test, P <.001). CONCLUSIONS: RPLND is associated with virtually no or low PM in patients with localized and regional disease. The PM rates for these 2 groups replicated those of Indiana University. In contrast, the PM rate of 6% for patients with distant metastases implies that RPLND for these higher risk patients should ideally be performed at centers of excellence, with the intent of reducing the PM rate.",
author = "Umberto Capitanio and Claudio Jeldres and Paul Perrotte and Hendrik Isbarn and Maxime Cr{\'e}pel and Vincent Cloutier and Sara Baillargeon-Gagne and Shariat, {Shahrokh F} and Alain Duclos and Philippe Arjane and Hugues Widmer and Fred Saad and Francesco Montorsi and Karakiewicz, {Pierre I}",
year = "2009",
language = "Deutsch",
volume = "74",
pages = "373--377",
journal = "UROLOGY",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Population-based Study of Perioperative Mortality After Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Germ Cell Tumors.

AU - Capitanio, Umberto

AU - Jeldres, Claudio

AU - Perrotte, Paul

AU - Isbarn, Hendrik

AU - Crépel, Maxime

AU - Cloutier, Vincent

AU - Baillargeon-Gagne, Sara

AU - Shariat, Shahrokh F

AU - Duclos, Alain

AU - Arjane, Philippe

AU - Widmer, Hugues

AU - Saad, Fred

AU - Montorsi, Francesco

AU - Karakiewicz, Pierre I

PY - 2009

Y1 - 2009

N2 - OBJECTIVES: To determine whether retroperitoneal lymphadenectomy (RPLND) perioperative mortality (PM) rates reported from a center of excellence (Indiana University: 0% for primary and 0.8% for postchemotherapy RPLND) are applicable to institutions at large. METHODS: We used the data from 882 assessable patients with nonseminomatous testicular germ cell tumor treated with RPLND from 1988 to 1997 accessed from the Surveillance, Epidemiology, and End Results (SEER) database. These data did not include data from Indiana University. The observed PM rates were stratified according to age and SEER stage. RESULTS: The median age at RPLND was 29 years. Of the 882 cases, 435 (49.3%) were performed for localized (Stage I), 380 (43.1%) for regional (Stage II), and 67 (7.6%) for metastatic (Stage III) SEER stage. Of the 882 patients, 7 patients died during the initial 90 days after RPLND, for a 0.8% PM rate. PM increased with increasing age: /=40 years, 2.7% (chi(2) trend test, P = .002). PM also increased with increasing stage: 0.0% for localized, 0.8% for regional, and 6.0% for metastatic disease (chi(2) trend test, P <.001). CONCLUSIONS: RPLND is associated with virtually no or low PM in patients with localized and regional disease. The PM rates for these 2 groups replicated those of Indiana University. In contrast, the PM rate of 6% for patients with distant metastases implies that RPLND for these higher risk patients should ideally be performed at centers of excellence, with the intent of reducing the PM rate.

AB - OBJECTIVES: To determine whether retroperitoneal lymphadenectomy (RPLND) perioperative mortality (PM) rates reported from a center of excellence (Indiana University: 0% for primary and 0.8% for postchemotherapy RPLND) are applicable to institutions at large. METHODS: We used the data from 882 assessable patients with nonseminomatous testicular germ cell tumor treated with RPLND from 1988 to 1997 accessed from the Surveillance, Epidemiology, and End Results (SEER) database. These data did not include data from Indiana University. The observed PM rates were stratified according to age and SEER stage. RESULTS: The median age at RPLND was 29 years. Of the 882 cases, 435 (49.3%) were performed for localized (Stage I), 380 (43.1%) for regional (Stage II), and 67 (7.6%) for metastatic (Stage III) SEER stage. Of the 882 patients, 7 patients died during the initial 90 days after RPLND, for a 0.8% PM rate. PM increased with increasing age: /=40 years, 2.7% (chi(2) trend test, P = .002). PM also increased with increasing stage: 0.0% for localized, 0.8% for regional, and 6.0% for metastatic disease (chi(2) trend test, P <.001). CONCLUSIONS: RPLND is associated with virtually no or low PM in patients with localized and regional disease. The PM rates for these 2 groups replicated those of Indiana University. In contrast, the PM rate of 6% for patients with distant metastases implies that RPLND for these higher risk patients should ideally be performed at centers of excellence, with the intent of reducing the PM rate.

M3 - SCORING: Zeitschriftenaufsatz

VL - 74

SP - 373

EP - 377

JO - UROLOGY

JF - UROLOGY

SN - 0090-4295

IS - 2

M1 - 2

ER -